Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech reported strong Phase 1 proof-of-concept data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. At the higher dose level (DL2), the therapy achieved a 100% objective response rate and an 83.3% complete response rate in six patients, with all responses ongoing at data cutoff. The study demonstrated dose-dependent in vivo CAR-T expansion without the need for lymphodepletion, and reported no dose-limiting toxicities, serious adverse events, or ICANS.
Key figures
- Drug Name
- LB2501
- Phase Of Trial
- Phase 1
- Orr dl2
- 100%
- Cr rate dl2
- 83.3%
- Orr overall
- 50.0%
- Patients dl1
- 6
- Patients dl2
- 6
- Crs incidence
- 66.7%
- Irr incidence
- 75.0%
- Patients dosed
- 12
- Cr rate overall
- 41.7%
- Car t persistence days
- 116
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.